Literature DB >> 7237864

Gentamicin and ticarcillin in subjects with end-stage renal disease. Comparison of two assay methods and evaluation of inactivation rate.

M E Russo, E Atkin-Thor.   

Abstract

Eight subjects with end-stage renal disease were given gentamicin alone (single dose) and in combination with ticarcillin (multiple doses) to determine to what extent ticarcillin inactivates gentamicin in vivo and when this inactivation becomes significant. Gentamicin serum concentrations were performed by both a rapid radioimmunoassay (1 1/2 hours) and a conventional bioassay (8 hours) to determine whether the bioassay results would be falsely lowered by ticarcillin. The results of the study showed that ticarcillin inactivates gentamicin in vivo with an inactivation rate of 0.01 hours(-1). This was demonstrated by a decrease in serum gentamicin levels which became significant at 12 hours after gentamicin was given, and a decrease in gentamicin half-life from 46 to 28 hours during ticarcillin administration. Ticarcillin did not interfere with the bioassay method of measuring gentamicin levels. Although ticarcillin inactivates gentamicin in subjects with end-stage renal disease, the serum level data of gentamicin suggest that supplemental doses of the aminoglycoside are not necessary for 48 hours after a single loading dose of gentamicin. Widely used microbiological assay procedures are reliable in determining gentamicin levels and do not appear to be falsely lowered by concurrent ticarcillin administration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237864

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.

Authors:  G R Aronoff; R A Brier; R S Sloan; M E Brier
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease.

Authors:  C E Halstenson; C A Hirata; K L Heim-Duthoy; P A Abraham; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Effect of piperacillin on tobramycin pharmacokinetics in patients with normal renal function.

Authors:  A Lau; M Lee; S Flascha; R Prasad; R Sharifi
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

4.  Comparative assessment of in vitro inactivation of gentamicin in the presence of carbenicillin by three different gentamicin assay methods.

Authors:  S C Ebert; J H Jorgensen; D J Drutz; W A Clementi
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

5.  In vitro inactivation of aminoglycosides by apalcillin.

Authors:  D N Wright; D C Hale; B Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

6.  Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease.

Authors:  C E Halstenson; M O Wong; C S Herman; K L Heim-Duthoy; M A Teal; M B Affrime; J H Kelloway; W F Keane; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.